Literature DB >> 33654067

Venetoclax treatment of patients with relapsed T-cell prolymphocytic leukemia.

Paul J Hampel1, Sameer A Parikh1, Timothy G Call1, Mithun V Shah1, N Nora Bennani1, Aref Al-Kali1, Kari G Rabe2, Yucai Wang1, Eli Muchtar1, Jose F Leis3, Saad S Kenderian1, Amber B Koehler1, Susan M Schwager1, Susan L Slager2, Neil E Kay1, Curtis A Hanson4, Daniel L Van Dyke4, Min Shi4, Wei Ding5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 33654067      PMCID： PMC7925672          DOI： 10.1038/s41408-021-00443-1

Source DB:  PubMed          Journal:  Blood Cancer J        ISSN： 2044-5385            Impact factor:   11.037


× No keyword cloud information.
  17 in total

1.  Bendamustine is effective in T-cell prolymphocytic leukaemia.

Authors:  Charles Herbaux; Philippe Genet; Krimo Bouabdallah; Jean-Michel Pignon; Houria Debarri; Stéphanie Guidez; Sarah Betrian; Xavier Leleu; Thierry Facon; Franck Morschhauser; Gandhi Damaj; Bruno Cazin; Loïc Ysebaert
Journal:  Br J Haematol       Date:  2014-10-15       Impact factor: 6.998

Review 2.  Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemia.

Authors:  Philipp B Staber; Marco Herling; Mar Bellido; Eric D Jacobsen; Matthew S Davids; Tapan Mahendra Kadia; Andrei Shustov; Olivier Tournilhac; Emmanuel Bachy; Francesco Zaja; Kimmo Porkka; Gregor Hoermann; Ingrid Simonitsch-Klupp; Claudia Haferlach; Stefan Kubicek; Marius E Mayerhoefer; Georg Hopfinger; Ulrich Jaeger; Claire Dearden
Journal:  Blood       Date:  2019-07-10       Impact factor: 22.113

3.  Discovery of novel drug sensitivities in T-PLL by high-throughput ex vivo drug testing and mutation profiling.

Authors:  E I Andersson; S Pützer; B Yadav; O Dufva; S Khan; L He; L Sellner; A Schrader; G Crispatzu; M Oleś; H Zhang; S Adnan-Awad; S Lagström; D Bellanger; J P Mpindi; S Eldfors; T Pemovska; P Pietarinen; A Lauhio; K Tomska; C Cuesta-Mateos; E Faber; S Koschmieder; T H Brümmendorf; S Kytölä; E-R Savolainen; T Siitonen; P Ellonen; O Kallioniemi; K Wennerberg; W Ding; M-H Stern; W Huber; S Anders; J Tang; T Aittokallio; T Zenz; M Herling; S Mustjoki
Journal:  Leukemia       Date:  2017-08-14       Impact factor: 11.528

4.  Allogeneic hematopoietic stem cell transplantation for T-prolymphocytic leukemia: a report from the French society for stem cell transplantation (SFGM-TC).

Authors:  Thierry Guillaume; Yves Beguin; Reza Tabrizi; Stéphanie Nguyen; Didier Blaise; Eric Deconinck; Rabah Redjoul; Jérôme Cornillon; Gaëlle Guillerm; Nathalie Contentin; Anne Sirvent; Pascal Turlure; Alexandra Salmon; Anne Huynh; Sylvie François; Régis Peffault de Latour; Ibrahim Yakoub-Agha; Mohamad Mohty
Journal:  Eur J Haematol       Date:  2014-09-13       Impact factor: 2.997

5.  Combining epigenetic therapy with venetoclax overcomes alemtuzumab resistance in T-cell prolymphocytic leukemia. A case report of a 26-year-old man with a prior history of T-cell acute lymphoblastic leukemia and GI-T lymphoma.

Authors:  Michael Asger Andersen; Rebecca Valentin; Lene Dissing Sjö; Line Borgwardt; Kjeld Schmiegelow; Mette Klarskov Andersen; Rasmus L Marvig; Christina Westmose Yde; Carsten Utoft Niemann
Journal:  Acta Oncol       Date:  2020-09-24       Impact factor: 4.089

6.  Impact of Alemtuzumab Therapy and Route of Administration in T-Prolymphocytic Leukemia: A Single-Center Experience.

Authors:  Moussab Damlaj; Nanna H Sulai; Jennifer L Oliveira; Rhett P Ketterling; Shahrukh Hashmi; Thomas Witzig; Grzegorz Nowakowski; Timothy G Call; Tait D Shanafelt; Wei Ding; William J Hogan; Mark R Litzow; Mrinal M Patnaik
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2015-08-05

7.  The role of pentostatin in the treatment of T-cell malignancies: analysis of response rate in 145 patients according to disease subtype.

Authors:  J Mercieca; E Matutes; C Dearden; K MacLennan; D Catovsky
Journal:  J Clin Oncol       Date:  1994-12       Impact factor: 44.544

8.  First-in-human response of BCL-2 inhibitor venetoclax in T-cell prolymphocytic leukemia.

Authors:  Bernd Boidol; Christoph Kornauth; Emiel van der Kouwe; Nicole Prutsch; Lukas Kazianka; Sinan Gültekin; Gregor Hoermann; Marius E Mayerhoefer; Georg Hopfinger; Alexander Hauswirth; Michael Panny; Marie-Bernadette Aretin; Bernadette Hilgarth; Wolfgang R Sperr; Peter Valent; Ingrid Simonitsch-Klupp; Richard Moriggl; Olaf Merkel; Lukas Kenner; Ulrich Jäger; Stefan Kubicek; Philipp B Staber
Journal:  Blood       Date:  2017-09-27       Impact factor: 22.113

9.  Dual dependence on BCL2 and MCL1 in T-cell prolymphocytic leukemia.

Authors:  Victoria M Smith; Oliver Lomas; Donna Constantine; Lianne Palmer; Anna H Schuh; David Bruce; Oksana Gonchar; Salvador Macip; Sandrine Jayne; Martin J S Dyer; Toby A Eyre
Journal:  Blood Adv       Date:  2020-02-11

10.  Feasibility and acceptability of electronic symptom surveillance with clinician feedback using the Patient-Reported Outcomes version of Common Terminology Criteria for Adverse Events (PRO-CTCAE) in Danish prostate cancer patients.

Authors:  Christina Baeksted; Helle Pappot; Aase Nissen; Niels Henrik Hjollund; Sandra A Mitchell; Ethan Basch; Pernille Envold Bidstrup; Susanne Oksbjerg Dalton; Christoffer Johansen
Journal:  J Patient Rep Outcomes       Date:  2017-09-12
View more
  1 in total

1.  Hijacking the Pathway: Perspectives in the Treatment of Mature T-cell Leukemias.

Authors:  Linus Wahnschaffe; Marco Herling
Journal:  Hemasphere       Date:  2021-06-01
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.